|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
73,583,000 |
Market
Cap: |
N/A |
Last
Volume: |
1,917,000 |
Avg
Vol: |
893,411 |
52
Week Range: |
$259.55 - $259.55 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Buggy Joseph J |
VP, Research |
|
2012-12-17 |
4 |
S |
$62.14 |
$3,106,840 |
D/D |
(50,000) |
6,701 |
|
- |
|
Buggy Joseph J |
VP, Research |
|
2012-12-17 |
4 |
OE |
$0.75 |
$37,500 |
D/D |
50,000 |
56,701 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2012-10-31 |
4 |
A |
$10.56 |
$7,242 |
D/D |
686 |
22,992 |
|
- |
|
Huh Christine |
VP, Human Resources |
|
2012-10-31 |
4 |
A |
$23.07 |
$21,247 |
D/D |
921 |
4,921 |
|
- |
|
Fardis Maria |
EVP, Operations and Alliances |
|
2012-10-31 |
4 |
A |
$10.56 |
$3,452 |
D/D |
327 |
3,476 |
|
- |
|
Mcgreivy Jesse |
VP, Clinical Science |
|
2012-10-31 |
4 |
A |
$23.07 |
$13,449 |
D/D |
583 |
583 |
|
- |
|
Sjovall Boultbee Paula S |
EVP, Sales and Marketing |
|
2012-10-31 |
4 |
A |
$23.07 |
$18,870 |
D/D |
818 |
818 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2012-10-31 |
4 |
A |
$10.56 |
$1,721 |
D/D |
163 |
325 |
|
- |
|
Erdtmann Rainer M |
VP, IR Education Training |
|
2012-10-31 |
4 |
A |
$10.56 |
$15,170 |
D/D |
1,437 |
27,485 |
|
- |
|
Kunkel Lori Anne |
Chief Medical Officer |
|
2012-10-31 |
4 |
A |
$23.07 |
$21,247 |
D/D |
921 |
1,921 |
|
- |
|
Buggy Joseph J |
VP, Research |
|
2012-10-31 |
4 |
A |
$10.56 |
$6,176 |
D/D |
585 |
6,701 |
|
- |
|
Clow Fong Wang |
VP Biostatistics Data MgmtOffi |
|
2012-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,012 |
|
- |
|
Fardis Maria |
EVP, Operations and AlliancesO |
|
2012-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,149 |
|
- |
|
Huh Christine |
VP, Human ResourcesOfficer |
|
2012-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,000 |
|
- |
|
Mehta Minesh |
Director |
|
2012-05-17 |
4 |
AS |
$30.00 |
$556,950 |
D/D |
(18,565) |
0 |
|
- |
|
Mehta Minesh |
Director |
|
2012-05-17 |
4 |
OE |
$5.76 |
$137,259 |
D/D |
18,565 |
973 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2012-05-08 |
4 |
OE |
$4.25 |
$7,969 |
D/D |
1,875 |
22,306 |
|
- |
|
Zanganeh Maky |
Chief Business Officer |
|
2012-04-30 |
4 |
A |
$10.56 |
$21,241 |
D/D |
2,012 |
228,095 |
|
- |
|
Loury David J |
Chief Scientific Officer |
|
2012-04-30 |
4 |
A |
$10.56 |
$1,710 |
D/D |
162 |
29,369 |
|
- |
|
Buggy Joseph J |
VP, Research |
|
2012-04-30 |
4 |
A |
$10.56 |
$1,225 |
D/D |
116 |
6,116 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2012-04-30 |
4 |
A |
$10.56 |
$4,803 |
D/D |
455 |
20,431 |
|
- |
|
Erdtmann Rainer M |
VP of Finance |
|
2012-04-30 |
4 |
A |
$10.56 |
$6,070 |
D/D |
575 |
26,048 |
|
- |
|
Asbury Mark |
VP and General Counsel |
|
2012-04-30 |
4 |
A |
$10.56 |
$15,065 |
D/D |
1,427 |
1,427 |
|
- |
|
Duggan Robert W |
Chairman and CEO |
|
2012-03-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(22,000) |
502,114 |
|
- |
|
Mehta Minesh |
Director |
|
2012-02-13 |
4 |
AS |
$25.00 |
$299,275 |
D/D |
(11,971) |
0 |
|
- |
|
364 Records found
|
|
Page 7 of 15 |
|
|